Logo image of TRML

TOURMALINE BIO INC (TRML) Stock Price, Quote, News and Overview

NASDAQ:TRML - Nasdaq - US89157D1054 - Common Stock - Currency: USD

19.77  +1.02 (+5.44%)

After market: 19.3 -0.47 (-2.38%)

TRML Quote, Performance and Key Statistics

TOURMALINE BIO INC

NASDAQ:TRML (7/25/2025, 8:00:01 PM)

After market: 19.3 -0.47 (-2.38%)

19.77

+1.02 (+5.44%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High29.79
52 Week Low11.56
Market Cap507.89M
Shares25.69M
Float20.05M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-07 2025-08-07/bmo
IPO05-07 2021-05-07


TRML short term performance overview.The bars show the price performance of TRML in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10 15

TRML long term performance overview.The bars show the price performance of TRML in the last 1, 2 and 3 years. 1 year 2 years 3 years 2 4 6 8 10

The current stock price of TRML is 19.77 USD. In the past month the price increased by 18.31%. In the past year, price increased by 10.14%.

TOURMALINE BIO INC / TRML Daily stock chart

TRML Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.53 336.11B
AMGN AMGEN INC 14.77 164.85B
GILD GILEAD SCIENCES INC 15.01 144.54B
VRTX VERTEX PHARMACEUTICALS INC N/A 120.61B
REGN REGENERON PHARMACEUTICALS 12.71 60.80B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 42.87B
ARGX ARGENX SE - ADR 102.95 36.15B
ONC BEONE MEDICINES LTD-ADR 7.43 31.54B
BNTX BIONTECH SE-ADR N/A 27.72B
SMMT SUMMIT THERAPEUTICS INC N/A 21.29B
INSM INSMED INC N/A 19.72B
BIIB BIOGEN INC 8.31 19.27B

About TRML

Company Profile

TRML logo image Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. The company is headquartered in New York City, New York and currently employs 74 full-time employees. The company went IPO on 2021-05-07. The firm is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. The Company’s initial product candidate is pacibekitug (TOUR006), a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. The company is focused on two strategic paths for TOUR006, the first of which is cardiovascular inflammation. Its second strategic path is thyroid eye disease (TED). TED is an autoimmune disease characterized by autoantibody-mediated activation of the tissues surrounding the eye, causing inflammation and disfigurement which can be sight-threatening in severe cases.

Company Info

TOURMALINE BIO INC

27 West 24th Street, Suite 702

New York City NEW YORK US

Employees: 70

TRML Company Website

TRML Investor Relations

Phone: 15023989250.0

TOURMALINE BIO INC / TRML FAQ

What is the stock price of TOURMALINE BIO INC today?

The current stock price of TRML is 19.77 USD. The price increased by 5.44% in the last trading session.


What is the ticker symbol for TOURMALINE BIO INC stock?

The exchange symbol of TOURMALINE BIO INC is TRML and it is listed on the Nasdaq exchange.


On which exchange is TRML stock listed?

TRML stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for TOURMALINE BIO INC stock?

17 analysts have analysed TRML and the average price target is 56.81 USD. This implies a price increase of 187.37% is expected in the next year compared to the current price of 19.77. Check the TOURMALINE BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is TOURMALINE BIO INC worth?

TOURMALINE BIO INC (TRML) has a market capitalization of 507.89M USD. This makes TRML a Small Cap stock.


How many employees does TOURMALINE BIO INC have?

TOURMALINE BIO INC (TRML) currently has 70 employees.


What are the support and resistance levels for TOURMALINE BIO INC (TRML) stock?

TOURMALINE BIO INC (TRML) has a support level at 18.97 and a resistance level at 19.78. Check the full technical report for a detailed analysis of TRML support and resistance levels.


Should I buy TOURMALINE BIO INC (TRML) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does TOURMALINE BIO INC (TRML) stock pay dividends?

TRML does not pay a dividend.


When does TOURMALINE BIO INC (TRML) report earnings?

TOURMALINE BIO INC (TRML) will report earnings on 2025-08-07, before the market open.


What is the Price/Earnings (PE) ratio of TOURMALINE BIO INC (TRML)?

TOURMALINE BIO INC (TRML) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.21).


What is the Short Interest ratio of TOURMALINE BIO INC (TRML) stock?

The outstanding short interest for TOURMALINE BIO INC (TRML) is 14.67% of its float. Check the ownership tab for more information on the TRML short interest.


TRML Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to TRML. When comparing the yearly performance of all stocks, TRML turns out to be only a medium performer in the overall market: it outperformed 68.97% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

TRML Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to TRML. While TRML has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TRML Financial Highlights

Over the last trailing twelve months TRML reported a non-GAAP Earnings per Share(EPS) of -3.21. The EPS increased by 39.8% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -28.82%
ROE -29.61%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-61.82%
Sales Q2Q%N/A
EPS 1Y (TTM)39.8%
Revenue 1Y (TTM)N/A

TRML Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 86% to TRML. The Buy consensus is the average rating of analysts ratings from 17 analysts.


Ownership
Inst Owners90.27%
Ins Owners10.35%
Short Float %14.67%
Short Ratio10.31
Analysts
Analysts85.88
Price Target56.81 (187.35%)
EPS Next Y-26.66%
Revenue Next YearN/A